{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:18:24Z","timestamp":1790878704080,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.esmoop.2024.104076","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T08:22:39Z","timestamp":1737534159000},"page":"104076","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["BRCA functional domains associated with high risk of multiple primary tumors and domain-related sensitivity to olaparib: the Prometheus Study"],"prefix":"10.1016","volume":"10","author":[{"given":"L.","family":"Incorvaia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Brando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.D.","family":"Bazan Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Congedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Ergasti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Castellana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Insalaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Contino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Gristina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Galvano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Fanale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Badalamenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Bazan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6178","key":"10.1016\/j.esmoop.2024.104076_bib1","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1126\/science.1252230","article-title":"Cancer suppression by the chromosome custodians, BRCA1 and BRCA2","volume":"343","author":"Venkitaraman","year":"2014","journal-title":"Science"},{"issue":"23","key":"10.1016\/j.esmoop.2024.104076_bib2","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.esmoop.2024.104076_bib3","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ygyno.2021.10.077","article-title":"Breast cancer surveillance following ovarian cancer in BRCA mutation carriers","volume":"164","author":"John","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"9337","key":"10.1016\/j.esmoop.2024.104076_bib4","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S0140-6736(02)11023-3","article-title":"Risk of ovarian cancer in breast-cancer patients with a family history of breast or ovarian cancer: a population-based cohort study","volume":"360","author":"Bergfeldt","year":"2002","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.esmoop.2024.104076_bib5","doi-asserted-by":"crossref","first-page":"198","DOI":"10.4149\/neo_2011_03_198","article-title":"BRCA1\/2 status and clinicopathologic characteristics of patients with double primary breast and ovarian cancer","volume":"58","author":"Cvelbar","year":"2011","journal-title":"Neoplasma"},{"key":"10.1016\/j.esmoop.2024.104076_bib6","article-title":"Breast cancer risk in BRCA mutation carriers after diagnosis of epithelial ovarian cancer is lower than in carriers without ovarian cancer","volume":"39","author":"Na\u00f1ez","year":"2021","journal-title":"Gynecol Oncol Rep"},{"issue":"1","key":"10.1016\/j.esmoop.2024.104076_bib8","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ygyno.2004.09.039","article-title":"The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers","volume":"96","author":"Metcalfe","year":"2005","journal-title":"Gynecol Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2024.104076_bib9","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/cncr.27842","article-title":"Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer","volume":"119","author":"Domchek","year":"2013","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.esmoop.2024.104076_bib10","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1001\/jamasurg.2014.1081","article-title":"Breast cancer following ovarian cancer in BRCA mutation carriers","volume":"149","author":"Gangi","year":"2014","journal-title":"JAMA Surg"},{"issue":"1","key":"10.1016\/j.esmoop.2024.104076_bib12","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nrc3181","article-title":"BRCA1 and BRCA2: different roles in a common pathway of genome protection","volume":"12","author":"Roy","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.esmoop.2024.104076_bib7","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920975326","article-title":"BRCA1\/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype-phenotype correlation in a cohort of 531 patients","volume":"12","author":"Incorvaia","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"13","key":"10.1016\/j.esmoop.2024.104076_bib11","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1001\/jama.2014.5985","article-title":"Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer","volume":"313","author":"Rebbeck","year":"2015","journal-title":"JAMA"},{"issue":"26","key":"10.1016\/j.esmoop.2024.104076_bib13","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.esmoop.2024.104076_bib14","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1200\/JCO.22.01549","article-title":"Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial","volume":"41","author":"DiSilvestro","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2024.104076_bib15","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1016\/j.esmoop.2024.104076_bib16","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1158\/1078-0432.CCR-16-2615","article-title":"Long-term responders on olaparib maintenance in high-grade serous ovarian cancer: clinical and molecular characterization","volume":"23","author":"Lheureux","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.esmoop.2024.104076_bib17","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.ccr.2011.11.014","article-title":"BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance","volume":"20","author":"Drost","year":"2011","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.esmoop.2024.104076_bib18","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1172\/JCI70196","article-title":"BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1","volume":"126","author":"Drost","year":"2016","journal-title":"J\u00a0Clin Invest"},{"issue":"7182","key":"10.1016\/j.esmoop.2024.104076_bib19","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/nature06548","article-title":"Resistance to therapy caused by intragenic deletion in BRCA2","volume":"451","author":"Edwards","year":"2008","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.esmoop.2024.104076_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100459","article-title":"Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies","volume":"7","author":"Russo","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2024.104076_bib21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.critrevonc.2019.05.012","article-title":"Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives","volume":"140","author":"Gori","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"issue":"11","key":"10.1016\/j.esmoop.2024.104076_bib22","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/humu.20880","article-title":"Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results","volume":"29","author":"Plon","year":"2008","journal-title":"Hum Mutat"},{"key":"10.1016\/j.esmoop.2024.104076_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.682445","article-title":"Prevalence and spectrum of germline BRCA1 and BRCA2 variants of uncertain significance in breast\/ovarian cancer: mysterious signals from the genome","volume":"11","author":"Fanale","year":"2021","journal-title":"Front Oncol"},{"issue":"Database issue","key":"10.1016\/j.esmoop.2024.104076_bib24","doi-asserted-by":"crossref","first-page":"D980","DOI":"10.1093\/nar\/gkt1113","article-title":"ClinVar: public archive of relationships among sequence variation and human phenotype","volume":"42","author":"Landrum","year":"2014","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"10.1016\/j.esmoop.2024.104076_bib25","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/humu.22981","article-title":"HGVS recommendations for the description of sequence variants: 2016 update","volume":"37","author":"den Dunnen","year":"2016","journal-title":"Hum Mutat"},{"issue":"6","key":"10.1016\/j.esmoop.2024.104076_bib26","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1001\/jamaoncol.2022.0476","article-title":"Expansion of cancer risk profile for BRCA1 and BRCA2 pathogenic variants","volume":"8","author":"Momozawa","year":"2022","journal-title":"JAMA Oncol"},{"issue":"14","key":"10.1016\/j.esmoop.2024.104076_bib27","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1200\/JCO.21.02112","article-title":"Cancer risks associated with BRCA1 and BRCA2 pathogenic variants","volume":"40","author":"Li","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.104076_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103567","article-title":"The challenge of the molecular tumor board empowerment in clinical oncology practice: a position paper on behalf of the AIOM-SIAPEC\/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies","volume":"169","author":"Russo","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.esmoop.2024.104076_bib29","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.67926","article-title":"Role of BRCA2 DNA-binding and C-terminal domain in its mobility and conformation in DNA repair","volume":"10","author":"Paul","year":"2021","journal-title":"Elife"},{"issue":"10","key":"10.1016\/j.esmoop.2024.104076_bib30","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1093\/nar\/gkab308","article-title":"Cancer-causing BRCA2 missense mutations disrupt an intracellular protein assembly mechanism to disable genome maintenance","volume":"49","author":"Lee","year":"2021","journal-title":"Nucleic Acids Res"},{"issue":"14","key":"10.1016\/j.esmoop.2024.104076_bib31","doi-asserted-by":"crossref","first-page":"7818","DOI":"10.1093\/nar\/gkaa555","article-title":"DSS1 and ssDNA regulate oligomerization of BRCA2","volume":"48","author":"Le","year":"2020","journal-title":"Nucleic Acids Res"},{"issue":"10","key":"10.1016\/j.esmoop.2024.104076_bib32","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1158\/2159-8290.CD-19-1485","article-title":"Clinical BRCA1\/2 reversion analysis identifies hotspot mutations and predicted neoantigens associated with therapy resistance","volume":"10","author":"Pettitt","year":"2020","journal-title":"Cancer Discov"},{"issue":"14","key":"10.1016\/j.esmoop.2024.104076_bib33","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1158\/1078-0432.CCR-22-3715","article-title":"Investigation of PARP inhibitor resistance based on serially collected circulating tumor DNA in patients with BRCA-mutated ovarian cancer","volume":"29","author":"Kim","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.esmoop.2024.104076_bib34","doi-asserted-by":"crossref","first-page":"23891","DOI":"10.18632\/oncotarget.14409","article-title":"\u201cBack to a false normality\u201d: new intriguing mechanisms of resistance to PARP inhibitors","volume":"8","author":"Incorvaia","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.esmoop.2024.104076_bib35","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.annonc.2022.11.003","article-title":"Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1\/ENGOT-ov25 trial subgroup exploratory analysis","volume":"34","author":"Labidi-Galy","year":"2023","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2024.104076_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100235","article-title":"Impact of deleterious variants in other genes beyond BRCA1\/2 detected in breast\/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge","volume":"6","author":"Bono","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2024.104076_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102650","article-title":"Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: still looking through a dirty glass window?","volume":"121","author":"Incorvaia","year":"2023","journal-title":"Cancer Treat Rev"},{"issue":"9","key":"10.1016\/j.esmoop.2024.104076_bib38","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.3390\/cancers12092415","article-title":"Detection of germline mutations in a cohort of 139 patients with bilateral breast cancer by multi-gene panel testing: impact of pathogenic variants in other genes beyond BRCA1\/2","volume":"12","author":"Fanale","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.esmoop.2024.104076_bib39","doi-asserted-by":"crossref","first-page":"4995","DOI":"10.1038\/s41467-020-18819-5","article-title":"Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome","volume":"11","author":"Hollis","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.esmoop.2024.104076_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103436","article-title":"The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM- SIAPEC\/IAP-SIBioC-SIF Italian Scientific Societies","volume":"165","author":"Russo","year":"2021","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924018465?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924018465?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T05:12:15Z","timestamp":1740633135000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924018465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2059702924018465"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.104076","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BRCA functional domains associated with high risk of multiple primary tumors and domain-related sensitivity to olaparib: the Prometheus Study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.104076","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"104076"}}